This is an intriguing finding since Everolimus is currently indicated and available for the treatment of renal cell cancer and pancreatic neuroendocrine tumors and could be of value for carefully selected patients with NRAS mutant neuroblastomas. The gene discussed is NRAS; the disease is pancreatic neuroendocrine tumor.